From Drugs of Abuse to Parkinsonism: The MPTP Mouse Model of Parkinson’s Disease - Drugs of Abuse: Neurological Reviews and Protocols - page 110

9. Agid, Y. (1991) Parkinson's disease: pathophysiology. Lancet 337, 1321-1324.
10. Fearnley, J. M., and Lees, A. J. (1991) Ageing and Parkinson's disease: substantia
nigra regional selectivity. Brain 114, 2283-2301.
11. Frost, J. J., Rosier, A. J., Reich, S. G., et al. (1993) Positron emission tomographic
imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked
declines in mild Parkinson's disease. Ann. Neurol. 34, 423-431.
12. Braak, H., Braak, E., Yilmazer, D., de Vos, R. A., Jansen, E. N., and Bohl, J.
(1996) Pattern of brain destruction in Parkinson's and Alzheimer's diseases.
J. Neural Transm. 103, 455-490.
13. Forno, L. S. (1996) Neuropathology of Parkinson's disease. J. Neuropathol. Exp.
Neurol. 55, 259-272.
14. Kuzuhara, S., Mori, H., Izumiyama, N., Yoshimura, M., and Ihara, Y. (1988) Lewy
bodies are ubiquitinated. A light and electron microscopic immunocytochemical
study. Acta Neuropathol. (Berl.) 75, 345-353.
15. Bancher, C., Lassmann, H., Budka, H., et al. (1989) An antigenic profi le of
Lewy bodies: immunocytochemical indication for protein phosphorylation and
ubiquitination. J. Neuropathol. Exp. Neurol. 48, 81-93.
16. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., and Goedert, M. (1998)
Alpha-synuclein in fi lamentous inclusions of Lewy bodies from Parkinson's disease
and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469-6473.
17. Gai, W. P., Yuan, H. X., Li, X. Q., Power, J. T., Blumbergs, P. C., and Jensen,
P. H. (2000) In situ and in vitro study of colocalization and segregation of alpha-
synuclein, ubiquitin, and lipids in Lewy bodies. Exp. Neurol. 166, 324-333.
18. Shimura, H., Schlossmacher, M. G., Hattori, N., et al. (2001) Ubiquitination of
a new form of alpha-synuclein by parkin from human brain: implications for
Parkinson's disease. Science 293, 263-269.
19. Ungerstedt, U. (1976) 6-Hydroxydopamine-induced degeneration of the nigro-
striatal dopamine pathway: the turning syndrome. Pharmacol. Ther. 2, 37-40.
20. Schwarting, R. K. and Huston, J. P. (1996) The unilateral 6-hydroxydopamine
lesion model in behavioral brain research. Analysis of functional defi cits, recovery
and treatments. Prog. Neurobiol. 50, 275-331.
21. Montastruc, J. L., Llau, M. E., Rascol, O., and Senard, J. M. (1994) Drug-induced
parkinsonism: a review. Fund. Clin. Pharmacol. 8, 293-306.
22. Ferrante, R. J., Schulz, J. B., Kowall, N. W., and Beal, M. F. (1997) Systemic
administration of rotenone produces selective damage in the striatum and globus
pallidus, but not in the substantia nigra. Brain Res. 753, 157-162.
23. Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., and
Greenamyre, J. T. (2000) Chronic systemic pesticide exposure reproduces features
of Parkinson's disease. Nat. Neurosci. 3, 1301-1306.
24. Corasaniti, M. T., Strongoli, M. C., Rotiroti, D., Bagetta, G., and Nistico, G.
(1998) Paraquat: a useful tool for the in vivo study of mechanisms of neuronal cell
death. Pharmacol. Toxicol. 83, 1-7.
25. Thiruchelvam, M., Richfi eld, E. K., Baggs, R. B., Tank, A. W., and Cory-Slechta,
D. A. (2000) The nigrostriatal dopaminergic system as a preferential target of